Zydus Lifesciences bags USFDA nod for HIV-1 drug Darunavir
Darunavir must be -co-administered with Ritonavir and with other antiretroviral agents.
Ahmedabad: Zydus Lifesciences Limited today announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets (USRLD: Prezista Tablets, 75 mg, 150 mg, 600 mg, and 800 mg).
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body. It is indicated for the treatment of HIV-1 infection in adult patients. It is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older.
It must be –co-administered with Ritonavir and with other antiretroviral agents.
The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad (India).
Darunavir Tablets, 75 mg, 150 mg, 600 mg, and 800 mg had annual sales of USD 275 mn in the United States (IQVIA MAT Oct. 2023). The group now has 383 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.
Read also: Zydus Lifesciences gets USFDA okay for acquired methemoglobinemia injection Methylene Blue
